LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalisation serves as the only volume to the market to bridge basic… Read more
LIMITED OFFER
Immediately download your ebook while waiting for your print delivery. No promo code needed.
AV
• Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flandres-Artois).
• Consulting, Partnering & Fund Raising, Founder, Managing Director, NxR Biotechnologies, Switzerland.
• Dr. Vertès is a strategy and business development consultant for cell therapeutic biotech companies, and works to enable seed funding in the field. Focusing on technology deployment and innovation commercialization, he has contributed to both industrial and pharmaceutical biotechnology, in different functions including research, manufacturing, contract research, and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche).
• Championed radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, and led in a scientific and business manner Roche’s global cell therapeutics strategy and implementation team resulting in Roche’s entry in 2010 in the field of regenerative medicine.
• Member, Industry Committee-Europe, Tissue Engineering and Regenerative Medicine International Society
• Co-Editor, Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies (Wiley, 2015).
ND
DS
• Responsible for all cell & gene therapy products, as well as previously developing Pfizer’s Regenerative Medicine program.
• PhD in Genetics from Harvard Medical School.
• Adjunct faculty member at Northeastern University.
NQ